[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hangzhou Sciwind Biosciences Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":98},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,66],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100626316","phase-3-a-study-of-xw003-in-obese-participants-with-obstructive-sleep-apnea-receiving-positive-airway-pressure-therapy-100626316",false,"NCT07434050","A Study of XW003 in Obese Participants With Obstructive Sleep Apnea Receiving Positive Airway Pressure Therapy","A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study to Assess the Efficacy and Safety of XW003 Injections in Obese Participants With Obstructive Sleep Apnea Receiving Positive Airway Pressure Therapy","Inclusion Criteria:\n\n1. Body mass index (BMI) ≥ 28.0 kg\u002Fm2;\n2. The results of PSG meet the diagnosis criteria of OSA and with an AHI≥15 at screening;\n3. Have been on PAP therapy for at least 3 consecutive months prior to screening and plan to continue PAP therapy during the study;\n4. Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight.\n\nExclusion Criteria:\n\n1. History of endocrine disorders which have significant impact on body weight;\n2. Diagnosis of diabetes (except gestational diabetes), ketoacidosis or hypertonic state\u002Fcoma;\n3. HbA1c ≥6.5% at screening;\n4. Fasting blood glucose ≥7.0 mmol\u002FL or 2-hour blood glucose ≥11.1 mmol\u002FL after oral glucose tolerance test (OGTT) at screening; participants with FBG ≥6.1 mmol\u002FL but \\\u003C7.0 mmol\u002FL require OGTT;\n5. Have diagnosis of Cheyne Stokes Respiration, or diagnosis of Central or Mixed Sleep Apnea with % of mixed or central apneas\u002Fhypopneas ≥50%;\n6. Respiratory and neuromuscular diseases that could interfere with the results of the trial;\n7. Diagnosis of Obesity Hypoventilation Syndrome or daytime hypercapnia;\n8. Change of body weight \\>5% within 3 months prior to screening (selfreported);\n9. Have a prior or planned surgical treatment for obesity (except liposuction or abdominoplasty if performed more than 1 year prior to screening);\n10. Have received any medication for body weight loss and blood glucose lowering or medication that could lead to significant body weight increase, within 3 months prior to screening.","ALL","18 Years","75 Years",{"count":20,"type":21},140,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The aim of the study is to assess the efficacy and safety of XW003 injections in obese participants with OSA receiving PAP",[27,28],"OSA - Obstructive Sleep Apnea","Obesity",[30,31,32,28,33],"XW003","Ecnoglutide","OSA","GLP-1","RECRUITING","2026-04-09",{"date":37,"type":38},"2026-04-13","ACTUAL",{"date":40,"type":38},"2026-03-02",{"date":42,"type":21},"2028-06-19",{"name":44,"class":45},"Hangzhou Sciwind Biosciences Co., Ltd.","INDUSTRY",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":56,"conditions":57,"keywords":58,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":46},"100622705","phase-3-a-study-of-xw003-in-obese-participants-with-obstructive-sleep-apnea-but-not-receive-positive-airway-pressure-therapy-100622705","NCT07387094","A Study of XW003 in Obese Participants With Obstructive Sleep Apnea But Not Receive Positive Airway Pressure Therapy","A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study to Assess the Efficacy and Safety of XW003 Injections in Obese Participants With Obstructive Sleep Apnea But Not Receive Positive Airway Pressure Therapy","Inclusion Criteria:\n\n1. Body mass index (BMI) ≥ 28.0 kg\u002Fm2;\n2. The results of PSG meet the diagnosis criteria of OSA and with an AHI ≥15 at screening;\n3. Participants must not have used PAP for at least 4 weeks prior to screening and not use PAP during the study;\n4. Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight.\n\nExclusion Criteria:\n\n1. History of endocrine disorders which have significant impact on body weight;\n2. Diagnosis of diabetes (except gestational diabetes), ketoacidosis or hypertonic state\u002Fcoma;\n3. HbA1c ≥6.5% at screening;\n4. Fasting blood glucose ≥7.0 mmol\u002FL or 2-hour blood glucose ≥11.1 mmol\u002FL after oral glucose tolerance test (OGTT) at screening; participants with FBG ≥6.1 mmol\u002FL but \\\u003C7.0 mmol\u002FL require OGTT;\n5. Have diagnosis of Cheyne Stokes Respiration, or diagnosis of Central or Mixed Sleep Apnea with % of mixed or central apneas\u002Fhypopneas ≥50%;\n6. Respiratory and neuromuscular diseases that could interfere with the results of the trial;\n7. Diagnosis of Obesity Hypoventilation Syndrome or daytime hypercapnia;\n8. Change of body weight \\>5% within 3 months prior to screening (self-reported);\n9. Have a prior or planned surgical treatment for obesity (except liposuction or abdominoplasty if performed more than 1 year prior to screening);\n10. Have received any medication for body weight loss and blood glucose lowering or medication that could lead to significant body weight increase, within 3 months prior to screening.",{"count":20,"type":21},[24],"The aim of the study is to assess the efficacy and safety of XW003 injections in obese participants with OSA but not receiving PAP",[27,28],[30,31,28,32,33],{"date":60,"type":38},"2026-04-14",{"date":62,"type":38},"2026-02-09",{"date":64,"type":21},"2027-12-16",{"name":44,"class":45},{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":73,"sex":16,"minAge":17,"maxAge":74,"enrollmentInfo":75,"targetDuration":4,"studyType":22,"phases":77,"briefSummary":80,"conditions":81,"keywords":84,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":46},"100611637","phase-1-a-phase-ibiia-study-to-evaluate-the-safety-tolerability-pharmacokinetics-and-pharmacodynamics-of-oral-ecnoglutide-tablets-in-chinese-participants-with-overweight-or-obesity-100611637","NCT07243171","A Phase Ib\u002FIIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity","A Multicenter, Multiple-dose Escalation, Randomized, Double-blind, Placebo-controlled Phase Ib\u002FIIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity","Inclusion Criteria:\n\n1. At the time of informed consent, with BMI in the range of 24.0 to 35.0 kg\u002Fm2 (including the threshold), body weight \\>60.0 kg for male, and weight \\>50.0 kg for female;\n2. Self-declaration of body weight change \\\u003C5% within 3 months prior to informed consent ;\n\nExclusion Criteria:\n\n1. Diagnosis of overweight or obesity due to endocrine disorders , such as Cushing's syndrome;\n2. Diagnosis of other endocrine disorders with clinical significance, including but not limited to hyperthyroidism or hypothyroidism, thyroid nodules (imaging shows TI-RADS≥ class 3), thyroid cancer, or personal or family history of type 2 multiple endocrine tumor syndrome (MEN2), etc.\n3. Diagnosis of cardiovascular or cerebrovascular diseases with clinical significance within 6 months prior to screening, including but not limited to acute stroke, acute coronary syndrome, heart failure, arrhythmia, etc.\n4. Diagnosis of severe gastrointestinal diseases, including but not limited to inflammatory bowel disease, active ulcers, irritable bowel syndrome, celiac disease, dyspepsia, diabetic gastroparesis, diabetic diarrhea, clinical gastric emptying abnormalities (such as pyloric obstruction), etc.\n5. History of major gastrointestinal surgery (except cholecystectomy or appendectomy), or metabolic surgery, or plan to undergo major surgery during the study period;\n6. HbA1c ≥6.5% or fasting blood glucose ≥7.0 mmol\u002FL, or OGTT 2-hour blood glucose ≥11.1 mmol\u002FL, at screening;\n7. Clinical laboratory test results with clinical significance",true,"65 Years",{"count":76,"type":21},84,[78,79],"PHASE1","PHASE2","The aim of the study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of oral ecnoglutide tablets in Chinese participants with overweight or obesity",[82,83],"Overweight and\u002For Obesity","Weight Management",[85,86,87,88,89],"ecnoglutide","glucagon-like peptide-1 (GLP-1)","obesity","overweight","weight management","2026-01-27",{"date":92,"type":38},"2026-01-28",{"date":94,"type":38},"2025-11-18",{"date":96,"type":21},"2026-11-22",{"name":44,"class":45},""]